Takeda Pharmaceutical Co (TSE:4502) Other Stockholders Equity: 円3,297,407 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4502 Takeda Pharmaceutical Co Ltd TSE:4502
64 GF Score
Price 円5,288.00
GF Value 円4,538.58
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Other Stockholders Equity?

Takeda Pharmaceutical Co TSE:4502 -0.73% 64 Other Stockholders Equity is 円3,297,407 Mil as of Mar. 2026. GuruFocus rates TSE:4502 with a GF Score™ of 64/100 and a GF Value™ of 円4,538.58 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Takeda Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was 円3,297,407 Mil.

Takeda Pharmaceutical Co's quarterly Other Stockholders Equity increased from Sep. 2025 (円2,605,314 Mil) to Dec. 2025 (円3,152,679 Mil) and increased from Dec. 2025 (円3,152,679 Mil) to Mar. 2026 (円3,297,407 Mil).

Takeda Pharmaceutical Co's annual Other Stockholders Equity declined from Mar. 2024 (円2,509,310 Mil) to Mar. 2025 (円2,351,915 Mil) but then increased from Mar. 2025 (円2,351,915 Mil) to Mar. 2026 (円3,297,407 Mil).

Takeda Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Other Stockholders Equity Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 934,174.00 1,508,118.00 2,509,310.00 2,351,915.00 3,297,407.00

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,351,915.00 2,347,471.00 2,605,314.00 3,152,679.00 3,297,407.00
TSE:4502
64GF Score
Takeda Pharmaceutical Co Ltd TSE:4502
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円3,297,407 Mil mean?
Takeda Pharmaceutical Co (TSE:4502) has a Other Stockholders Equity of 円3,297,407 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Other Stockholders Equity too high?
Takeda Pharmaceutical Co's current Other Stockholders Equity is 円3,297,407 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Other Stockholders Equity compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Other Stockholders Equity of 円3,297,407 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Other Stockholders Equity is 円3,297,407 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,538.58, compared to a current price of 円5,288.00 — trading 16.5% above its estimated fair value. The current Other Stockholders Equity is 円3,297,407 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 64/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current Other Stockholders Equity is 円3,297,407 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of 円5,288.00 is trading 16.5% above its estimated GF Value™ of 円4,538.58. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4502:

  • Other Stockholders Equity: 円3,297,407 Mil
  • GF Value™: 円4,538.58 vs. price of 円5,288.00 (16.5% above fair value)
  • GF Score™: 64/100 with 9 warning signs

No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
64GF Score

Get the complete analysis for TSE:4502

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円5,288.00
Price
円4,538.58
GF Value